Oncolytic Viruses (Seprehvir™, Seprehvec™)

Sorrento’s oncolytic viral vector assets are a modified version of the common human herpes simplex virus (HSV-1). Seprehvir has been designed with the ability to specifically destroy tumor cells while also stimulating anti-tumor patient immune responses. As part of its global clinical development program, Seprehvir has been administered to over 100 adult and pediatric patients in a variety of solid tumors including glioblastoma, mesothelioma, melanoma, head and neck cancer, pediatric sarcomas and pediatric neuroblastomas.

A key advantage of Seprehvir, as compared to other HSV-based oncolytic therapies, is that it has been safely administered intravenously, intratumorally and by loco-regional infusion to specifically tailor the therapy to a patient’s cancer.

The Seprehvec asset is a future generation project which aims to provide additional therapeutic options and can rapidly generate novel oncolytic immunotherapies:

• “Targeted” specifically to certain types of tumor cells
• “Armed” with additional genes to enhance the destruction of tumor cells
• Multi-functional “targeted” and “armed” variants with enhanced cell killing and immuno-stimulatory activities